Dr. Campagnaro is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1500 E Medical Center Dr
Ann Arbor, MI 48109Phone+1 734-936-4000
Education & Training
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 2004 - 2007
University of Texas Medical Branch HospitalsResidency, Internal Medicine, 2000 - 2003
Louisiana State University School of Medicine in New OrleansClass of 2000
Certifications & Licensure
MI State Medical License 2007 - 2026
OH State Medical License 2009 - 2019
TX State Medical License 2004 - 2010- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Clinical Trials
- Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma Start of enrollment: 2010 Jun 01
- Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Start of enrollment: 2011 Jan 24
- Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma Start of enrollment: 2010 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 96 citationsNCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022.Natalie S Callander, Muhamed Baljevic, Kehinde Adekola, Larry D Anderson, Erica Campagnaro
Journal of the National Comprehensive Cancer Network. 2022-01-01 - 14 citationsOptimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma.Emily K Hoylman, Anna Brown, Anthony J. Perissinotti, Bernard L. Marini, Matthew J. Pianko
Leukemia & Lymphoma. 2020-02-23 - 16 citationsMultiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.Shaji K Kumar, Natalie S Callander, Kehinde Adekola, Larry D Anderson Jr, Muhamed Baljevic
Journal of the National Comprehensive Cancer Network. 2023-12-01
Abstracts/Posters
- Circulating Tumor DNA in the Peripheral Blood As Early Predictor of Clinical Outcome in Relapsed/ Refractory Multiple MyelomaErica L. Campagnaro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Translational and Clinical Evidence of a Differentiated Profile for the Novel CELMoD, Iberdomide (CC-220)Erica L. Campagnaro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for ImmunotherapyErica L. Campagnaro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
